eligibility_summary
Eligible: ≥65 with IMWG-defined, measurable MM, ECOG 0–2, not a candidate for high‑dose chemo/ASCT, adequate labs, consent/adherence. Exclude: CNS MM, plasma cell leukemia, WM, POEMS, AL amyloidosis, MDS/other B‑cell malignancy, other active/high‑risk cancers, recent stroke/TIA/seizure, major cardiac disease, COPD/asthma FEV1<50%, recent RT, high steroids, live vaccine, prior MM therapy, HIV/HBV/HCV, WOCBP, recent/planned major surgery, drug hypersensitivity. Male contraception, no sperm donation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, open-label trial in newly diagnosed, transplant-ineligible elderly multiple myeloma: two cohorts test subcutaneous teclistamab + subcutaneous daratumumab (Tec-Dara) or teclistamab + oral lenalidomide (Tec-Len). Teclistamab: bispecific monoclonal antibody that binds BCMA on myeloma plasma cells and CD3 on T cells, redirecting T-cell cytotoxicity (T-cell engager). Daratumumab: anti-CD38 monoclonal antibody mediating ADCC, CDC, ADCP and depleting immunosuppressive CD38+ cells. Lenalidomide: immunomodulatory drug (IMiD) that binds cereblon, driving IKZF1/IKZF3 degradation, enhancing T/NK activation and anti-myeloma activity. Targets/pathways: BCMA+ plasma cells, CD3+ T cells, CD38+ tumor/immune cells, cereblon–IKZF pathway, goal is high VGPR+ rates with acceptable safety.